Clinical Trial Update: Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab and erlotinib followed by cisplatin or carboplatin and gemcitabine in newly diagnosed or recurrent stage IIIB/IV non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• ERLOTINIB (Erlotinib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED